Neurol. praxi. 2026;27(2):119-124 | DOI: 10.36290/neu.2025.082

Current genetic therapy options for transthyretin amyloidosis

prof. MUDr. Eva Vlčková, Ph.D.
Neurologická klinika Lékařské fakulty Masarykovy univerzity a Fakultní nemocnice Brno

Transthyretin amyloidosis (ATTR) is a severe, progressive multisystem disorder caused by the deposition of amyloid fibrils derived from pathologically unstable transthyretin in various tissues. Clinically, it most commonly manifests as rapidly progressive axonal sensory‑motor polyneuropathy with early autonomic nervous system involvement and/or cardiomyopathy. The development of disease‑modifying therapies, particularly gene "silencers" (molecules that suppress the expression of a specific gene at the mRNA level) based on small interfering RNAs (patisiran, vutrisiran) and antisense oligonucleotides (inotersen, eplontersen), has fundamentally changed the prognosis of affected patients. These agents reduce hepatic transthyretin synthesis, slow the progression of neuropathy or cardiomyopathy, and improve quality of life. This article summarizes the current options for genetic therapy of ATTR in the Czech Republic and discusses the perspectives of emerging therapeutic approaches.

Keywords: prealbumin, amyloidosis, polyneuropathy, cardiomyopathy, small interfering RNA, antisense oligonucleotides, genetic therapy.

Received: December 12, 2025; Revised: December 12, 2025; Accepted: December 15, 2025; Prepublished online: December 15, 2025; Published: April 29, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vlčková E. Current genetic therapy options for transthyretin amyloidosis. Neurol. praxi. 2026;27(2):119-124. doi: 10.36290/neu.2025.082.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 29.4.2027

    References

    1. Adams D, Sekijima Y, Conceição I, et al. Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment. Lancet Neurol. 2023;22:1061‑1074. doi:10.1016/S1474‑4422(23)00334‑4. Go to original source...
    2. Benson MD, Waddington‑Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22‑31. doi:10.1056/NEJMoa1716793. Go to original source... Go to PubMed...
    3. Coelho T, Maia LF, da Silva AM, et al. Long‑term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260:2802‑2814. doi:10.1007/s00415-013-7051-7. Go to original source... Go to PubMed...
    4. Di Stefano V, Guaraldi P, Romano A, et al. Patisiran in ATTRv amyloidosis with polyneuropathy: "PatisiranItaly" multicenter observational study. J Neurol. 2025;272:209‑218. doi:10.1007/s00415‑025‑12950‑3. Go to original source...
    5. European Medicines Agency. Amvuttra (vutrisiran): EPAR Product information. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/amvuttra. Citováno 12. 12. 2025.
    6. European Medicines Agency. Onpattro (patisiran): EPAR Product information. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/onpattro. Citováno 12. 12. 2025.
    7. European Medicines Agency. Tegsedi (inotersen): EPAR Product information. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tegsedi. Citováno 12. 12. 2025.
    8. European Medicines Agency. Vyndaqel (tafamidis): EPAR Product information. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel. Citováno 12.12.2025.
    9. European Medicines Agency. Wainzua (eplontersen): EPAR Product information. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/wainzua. Citováno 12. 12. 2025.
    10. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post‑transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9(2):102‑114. doi:10.1038/nrg2290. Go to original source...
    11. Hellenbart EL, Ipema HJ, Rodriguez‑Ziccardi MC, et al. Disease‑modifying therapies for amyloid transthyretin cardiomyopathy: current and emerging medications. Pharmacotherapy. 2025;45:124‑144. doi:10.1002/phar.4639. Go to original source... Go to PubMed...
    12. Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet. 1993;341(8853):1113‑1116. doi:10.1016/0140‑6736(93)93127‑M Go to original source...
    13. Johnson SM, Connelly S, Fearns C, et al. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory‑agency‑approved drug. J Mol Biol. 2012;421:185‑203. doi: 10.1016/j.jmb.2011.12.060. Go to original source... Go to PubMed...
    14. Margolin E, Stern LK, Argiro A, et al. Current and future treatment landscape of transthyretin amyloid cardiomyopathy. Cardiol Ther. 2025;14:1‑29. doi:10.1007/s40119‑025‑00424‑6. Go to original source...
    15. Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12:e006075. doi: 10.1161/CIRCHEARTFAILURE.119.006075. Go to original source... Go to PubMed...
    16. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583‑596. doi: 10.1056/NEJMra023144. Go to original source... Go to PubMed...
    17. Obici L, Perfetti V, Palladini G, et al. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta. 2005;1753:11‑22. doi: 10.1016/j.bbapap.2005.08.014. Go to original source... Go to PubMed...
    18. Planté‑Bordeneuve V. Transthyretin familial amyloid polyneuropathy: an update. J Neurol. 2018;265:976‑983. doi:10.1007/s00415-017-8708-4. Go to original source...
    19. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126:1286‑1300. doi:10.1161/CIRCULATIONAHA.111.078915. Go to original source...
    20. Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease‑modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86:1036‑1043. doi:10.1136/jnnp-2014-308724. Go to original source...
    21. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification. Amyloid. 2016;23:209‑213. doi:10.1080/13506129.2016.1257986. Go to original source... Go to PubMed...
    22. U.S. Food and Drug Administration. Amvuttra (vutrisiran): Drugs@FDA Listing. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process. Citováno 12. 12. 2025.
    23. U.S. Food and Drug Administration. Onpattro (patisiran): Drugs@FDA Listing. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210922. Citováno 12. 12. 2025.
    24. U.S. Food and Drug Administration. Tegsedi (inotersen): Drugs@FDA Listing. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process. Citováno 12. 12. 2025.
    25. U.S. Food and Drug Administration. Vyndaqel (tafamidis): Drugs@FDA Listing. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211996. Citováno 12. 12. 2025.
    26. U.S. Food and Drug Administration. Wainua (eplontersen): Drugs@FDA Listing. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process. Citováno 12. 12. 2025.
    27. Yamashita T, Ando Y, Obayashi K, et al. Long‑term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology. 2012;78(9):637‑643. doi:10.1212/WNL.0b013e318248df18. Go to original source... Go to PubMed...
    28. Zamore PD, Haley B. Ribo‑gnome: the big world of small RNAs. Science. 2005;309:1519‑1524 doi:10.1126/science.1111444. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.